Biomea Fusion, Inc. (BMEA)
0.5803
+0.02
(+3.13%)
USD |
NASDAQ |
Nov 13, 16:00
0.5803
0.00 (0.00%)
After-Hours: 19:59
Biomea Fusion Enterprise Value : 14.63M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 14.63M |
| November 11, 2026 | 18.13M |
| November 10, 2026 | 13.49M |
| November 09, 2026 | 16.98M |
| November 06, 2026 | 14.93M |
| November 05, 2026 | 16.43M |
| November 04, 2026 | 18.21M |
| November 03, 2026 | 19.07M |
| November 02, 2026 | 21.69M |
| October 30, 2026 | 20.21M |
| October 29, 2026 | 19.00M |
| October 28, 2026 | 20.81M |
| October 27, 2026 | 20.42M |
| October 26, 2026 | 19.93M |
| October 23, 2026 | 17.35M |
| October 22, 2026 | 16.25M |
| October 21, 2026 | 23.89M |
| October 20, 2026 | 27.20M |
| October 19, 2026 | 34.46M |
| October 16, 2026 | 36.88M |
| October 15, 2026 | 34.52M |
| October 14, 2026 | 34.35M |
| October 13, 2026 | 65.31M |
| October 12, 2026 | 72.58M |
| October 09, 2026 | 76.94M |
| Date | Value |
|---|---|
| October 08, 2026 | 73.30M |
| October 07, 2026 | 69.67M |
| October 06, 2026 | 64.58M |
| October 05, 2026 | 68.22M |
| October 02, 2026 | 66.04M |
| October 01, 2026 | 68.22M |
| September 30, 2026 | 70.40M |
| September 29, 2026 | 57.01M |
| September 28, 2026 | 59.19M |
| September 25, 2026 | 61.36M |
| September 24, 2026 | 73.68M |
| September 23, 2026 | 70.06M |
| September 22, 2026 | 88.91M |
| September 21, 2026 | 89.63M |
| September 18, 2026 | 98.33M |
| September 17, 2026 | 95.43M |
| September 16, 2026 | 91.81M |
| September 15, 2026 | 96.16M |
| September 14, 2026 | 94.71M |
| September 11, 2026 | 91.81M |
| September 10, 2026 | 88.91M |
| September 09, 2026 | 99.42M |
| September 08, 2026 | 105.58M |
| September 04, 2026 | 112.83M |
| September 03, 2026 | 104.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| REGENXBIO, Inc. | 531.96M |
| Compass Therapeutics, Inc. | -6.152M |
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 166.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.183M |
| Total Expenses (Quarterly) | 6.183M |
| EPS Diluted (Quarterly) | -0.0852 |
| Earnings Yield | -53.11% |
| Normalized Earnings Yield | -102.96 |